Our Products

HLS is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties.

Product Pipeline

Clozaril Schizophrenia U.S./Canada Acquired 2015 Marketed
Absorica Acne U.S. Acquired 2016 Marketed by a third party
Vascepa CV risk reduction Canada Approved 2019 Marketed
CSAN Pronto WBC Point-of-Care Diagnostic Canada Approved 2019 Marketed
Trinomia CV risk reduction Canada In-licensed 2017 Submission under review
Perseris Schizophrenia Canada In-licensed 2019 Submission under review

For U.S. Residents, click here for commercial product information.

For Canadian Residents, please click on the Canadian flag above for more commercial product information.

Brand names you know. Safe and effective results you trust.